JP2016527284A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527284A5
JP2016527284A5 JP2016532244A JP2016532244A JP2016527284A5 JP 2016527284 A5 JP2016527284 A5 JP 2016527284A5 JP 2016532244 A JP2016532244 A JP 2016532244A JP 2016532244 A JP2016532244 A JP 2016532244A JP 2016527284 A5 JP2016527284 A5 JP 2016527284A5
Authority
JP
Japan
Prior art keywords
intra
pharmaceutical formulation
pepstatin
prodrugs
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532244A
Other languages
English (en)
Japanese (ja)
Other versions
JP6336067B2 (ja
JP2016527284A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/001861 external-priority patent/WO2015018472A1/de
Publication of JP2016527284A publication Critical patent/JP2016527284A/ja
Publication of JP2016527284A5 publication Critical patent/JP2016527284A5/ja
Application granted granted Critical
Publication of JP6336067B2 publication Critical patent/JP6336067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532244A 2013-08-06 2014-07-07 関節症の場合のペプスタチンの関節内適応 Expired - Fee Related JP6336067B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003923 2013-08-06
EP13003923.3 2013-08-06
PCT/EP2014/001861 WO2015018472A1 (de) 2013-08-06 2014-07-07 Intraartikuläre applikation von pepstatin bei arthrose

Publications (3)

Publication Number Publication Date
JP2016527284A JP2016527284A (ja) 2016-09-08
JP2016527284A5 true JP2016527284A5 (https=) 2017-08-17
JP6336067B2 JP6336067B2 (ja) 2018-06-06

Family

ID=48948200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532244A Expired - Fee Related JP6336067B2 (ja) 2013-08-06 2014-07-07 関節症の場合のペプスタチンの関節内適応

Country Status (9)

Country Link
US (2) US9750784B2 (https=)
EP (1) EP3030250B1 (https=)
JP (1) JP6336067B2 (https=)
CN (1) CN105451754A (https=)
AU (1) AU2014304950B2 (https=)
CA (1) CA2920420C (https=)
ES (1) ES2759060T3 (https=)
IL (1) IL243983B (https=)
WO (1) WO2015018472A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7541746B2 (ja) * 2019-05-21 2024-08-29 国立大学法人 東京大学 脳腫瘍の検出用蛍光プローブ

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906085A (en) * 1973-05-21 1975-09-16 Lilly Co Eli Determination of hypertension associated with elevated renin levels
CA1286846C (en) 1985-02-12 1991-07-23 Catherine Cazaubon Peptide derivatives which inhibit renin and acid proteases
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
CA2280096A1 (en) 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US5962506A (en) 1997-07-07 1999-10-05 Pharmacopeia, Inc. Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
JP2000300266A (ja) * 1999-04-20 2000-10-31 St Marianna Univ School Of Medicine ポリペプチド及びdna
US7132568B2 (en) 2002-06-17 2006-11-07 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
ES2323068T3 (es) 2003-08-08 2009-07-06 Schering Corporation Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida.
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
GB0325830D0 (en) 2003-11-05 2003-12-10 Novartis Ag Organic compounds
JP2007528404A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ,インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−2−ヒドロキシ−3−ジアミノアルカン、ならびにベンズアミド−2−ヒドロキシ−3−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
US20080132477A1 (en) 2005-01-13 2008-06-05 Claudia Betschart Macrocyclic Compounds Useful as Bace Inhibitors
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
EP1745776A1 (en) 2005-07-20 2007-01-24 Speedel Experimenta AG Aminoalcohols as therapeutic compounds
EP1745777A1 (en) 2005-07-20 2007-01-24 Speedel Experimenta AG Amido-aminoalcohols as therapeutic compounds
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
EP1872780A3 (en) 2006-06-14 2008-04-30 Speedel Experimenta AG Omega-Phenyloctanamides as therapeutic compounds
EP1867329A3 (en) 2006-06-14 2008-05-07 Speedel Experimenta AG 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds
EP1987834A3 (en) 2007-02-13 2008-11-19 Speedel Experimenta AG Substituted piperidines as therapeutic compounds
WO2008119772A1 (en) 2007-03-30 2008-10-09 Medivir Ab Amide derivatives as inhibitors of aspartyl proteases
WO2009013293A1 (en) 2007-07-24 2009-01-29 Novartis Ag Substituted cyclohexanecarboxamides useful as bace inhibitors
MX2013009064A (es) * 2011-02-08 2013-10-01 Merck Patent Gmbh Derivados de aminostatina para el tratamiento de artrosis.
US20150225369A1 (en) * 2012-08-29 2015-08-13 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis

Similar Documents

Publication Publication Date Title
CY1124878T1 (el) Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης
EA202190115A1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения
HRP20211543T1 (hr) Derivati kinazolina koji se koriste za liječenje hiv-a
RU2018114447A (ru) Введение дейтерированных усилителей cftr
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
WO2015120110A3 (en) Novel pharmaceutical formulations
RU2013121788A (ru) Ингибиторы репликации вич
JP2014526503A5 (https=)
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
WO2017091767A3 (en) Drug formulations for cancer treatment
JP2015502926A5 (https=)
FI3500241T3 (fi) Yhdistelmähoito copd:lle
EA202192322A1 (ru) Фармацевтические составы
JP2017507142A5 (https=)
RU2016132762A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
FI3383385T4 (fi) Melflufeeniannoskuureja syöpään
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
JP2016515550A5 (https=)
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
JP2016512247A5 (https=)
JP2016505050A5 (https=)
JP2014148552A5 (https=)